Genomics Reporting Implementation Guide
4.0.0-cibuild - CI Build
Genomics Reporting Implementation Guide
4.0.0-cibuild - CI Build
Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 4.0.0-cibuild built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
Profile: Genomic Report
| When For | 2023-02-02 |
| Performers | Practitioner Test Dolin Organization My Test Pathology Laboratories |
| Identifier | Accession ID/23-0000345 |
Report Details
| Code | Value | Flags | Note | When For | Reported |
| Genetic variant assessment | Present | Final | 2023-02-01 | ||
| Genetic variant assessment | Present | Final | 2023-02-01 | ||
| Genetic variant assessment | Present | Final | 2023-02-01 | ||
| Genetic variant assessment | Present | Final | 2023-02-01 | ||
| Genetic variant assessment | Present | Final | 2023-02-01 | ||
| Genetic variant assessment | Present | Final | 2023-02-01 | ||
| Genetic variant assessment | Present | Final | 2023-02-01 | ||
| Genetic variant assessment | Present | Final | 2023-02-01 | ||
| Diagnostic Implication | Final | 2023-02-01 | |||
| Diagnostic Implication | Final | 2023-02-01 | |||
| Diagnostic Implication | Final | 2023-02-01 | |||
| Diagnostic Implication | Final | 2023-02-01 | |||
| Diagnostic Implication | Final | 2023-02-01 | |||
| Diagnostic Implication | Final | 2023-02-01 | |||
| Diagnostic Implication | Final | 2023-02-01 | |||
| Diagnostic Implication | Final | 2023-02-01 | |||
| Therapeutic Implication | Final | 2023-02-01 | |||
| Therapeutic Implication | Final | 2023-02-01 | |||
| Therapeutic Implication | Final | 2023-02-01 | |||
| Therapeutic Implication | Final | 2023-02-01 | |||
| Therapeutic Implication | Final | 2023-02-01 | |||
| Molecular Consequence | Final | 2023-02-01 | |||
| Molecular Consequence | Final | 2023-02-01 | |||
| Molecular Consequence | Final | 2023-02-01 | |||
| Molecular Consequence | Final | 2023-02-01 | |||
| Molecular Consequence | Final | 2023-02-01 | |||
| Molecular Consequence | Final | 2023-02-01 | |||
| Molecular Consequence | Final | 2023-02-01 | |||
| Molecular Consequence | Final | 2023-02-01 | |||
| Mutations/Megabase [# Ratio] in Tumor | 29.8 | Final | 2023-02-01 | ||
| Microsatellite instability [Interpretation] in Cancer specimen Qualitative | MSI-H | Final | 2023-02-01 | ||
| PD-L1 by clone 22C3 in Tissue by Immune stain Report | Positive | Final |
| 2023-02-01 | |
| Haplotype Name | HLA-A*24:02:01:01 | Final | 2023-02-01 | 2023-02-01 00:00:00-0500 | |
| Haplotype Name | HLA-A*02:06 | Final | 2023-02-01 | 2023-02-01 00:00:00-0500 | |
| Haplotype Name | HLA-B*35:01 | Final | 2023-02-01 | 2023-02-01 00:00:00-0500 | |
| Haplotype Name | HLA-B*35:01 | Final | 2023-02-01 | 2023-02-01 00:00:00-0500 | |
| Haplotype Name | HLA-C*03:03 | Final | 2023-02-01 | 2023-02-01 00:00:00-0500 | |
| Haplotype Name | HLA-C*15:02 | Final | 2023-02-01 | 2023-02-01 00:00:00-0500 |
Patient is positive for Tier 1 / Level A variants, including variants with FDA-approved indications.
Coded Conclusions:
IG © 2025+ HL7 International / Clinical Genomics. Package hl7.fhir.uv.genomics-reporting#4.0.0-cibuild based on FHIR 6.0.0-ballot3. Generated 2025-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change